Kerins Patrick J's Form 4 filing
Sagimet Biosciences Inc. (SGMT) · filed Jul 20, 2023
- Accession no.
- 0001209191-23-042970
- Filed
- Jul 20, 2023, 6:56 PM ET
- Trade date
- Jul 18, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 7 derivative transactions. Open-market purchases total $480.0K. Open-market sales total $10.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kerins Patrick JCIK 0001235112 | 10% Owner |
| Sandell Scott DCIK 0001237289 | 10% Owner |
| Baskett ForestCIK 0001277631 | 10% Owner |
| New Enterprise Associates 13 LPCIK 0001452907 | 10% Owner |
| NEA 13 GP, LtdCIK 0001460751 | 10% Owner |
| NEA Partners 13, Limited PartnershipCIK 0001460752 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 18, 2023 | Common Stock | JOtherDisposed | −37,676 | –F1 | – | 0 | Direct | |
| Jul 18, 2023 | Series A Common Stock | JOtherAcquired | +37,676 | –F1 | – | 37,676 | Direct | |
| Jul 18, 2023 | Series A Common Stock | CConversionAcquired | +3,769,857 | –F3 | – | 3,807,533 | Direct | |
| Jul 18, 2023 | Series A Common Stock | XIn-the-money exerciseAcquired | +13,404 | $0.7948F4 | +$10,653.5 | 3,820,937 | Direct | |
| Jul 18, 2023 | Series A Common Stock | SSaleDisposed | −662 | $16.00F4 | −$10,592 | 3,820,275 | Direct | |
| Jul 18, 2023 | Series A Common Stock | PPurchaseAcquired | +30,000 | $16.00 | +$480,000 | 3,850,275 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 18, 2023 | Common Stock | CConversionDisposed | −16,370 | $0.00 | $0 | 0 | Direct | |
| Jul 18, 2023 | Common Stock | CConversionDisposed | −142,974 | $0.00 | $0 | 0 | Direct | |
| Jul 18, 2023 | Common Stock | CConversionDisposed | −142,976 | $0.00 | $0 | 0 | Direct | |
| Jul 18, 2023 | Common Stock | CConversionDisposed | −184,440 | $0.00 | $0 | 0 | Direct | |
| Jul 18, 2023 | Common Stock | CConversionDisposed | −2,993,189 | $0.00 | $0 | 0 | Direct | |
| Jul 18, 2023 | Common Stock | CConversionDisposed | −289,908 | $0.00 | $0 | 0 | Direct | |
| Jul 18, 2023 | Common Stock | XIn-the-money exerciseDisposed | −13,404 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was reclassified into one share of Series A Common Stock.
Referenced by the price of 2 transactions in Table I.
- F3
Upon closing of the Issuer's initial public offering, each share of Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into Series A Common Stock. The Preferred Stock had no expiration date.
Referenced by the price of 1 transaction in Table I.
- F4
The Common Stock Warrants automatically exercised in connection with the closing of the Issuer's initial public offering for such number of shares issuable pursuant to a cashless net exercise provision, resulting in the Issuer withholding 662 of the warrant shares to pay the exercise price and issuing to NEA 13 the remaining 12,742 shares, after deducting the aggregate exercise price.
Referenced by the price of 2 transactions in Table I.